Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
InspireMD Inc - SIC # 3845 - ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
NSPR
Nasdaq
3845
https://www.inspiremd.com/en/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for InspireMD Inc
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
- Mar 26th, 2024 11:00 am
InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript
- Mar 7th, 2024 3:36 pm
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
- Mar 6th, 2024 12:00 pm
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
- Feb 28th, 2024 12:00 pm
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
- Feb 12th, 2024 12:00 pm
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
- Jan 31st, 2024 12:00 pm
We're Hopeful That InspireMD (NASDAQ:NSPR) Will Use Its Cash Wisely
- Jan 23rd, 2024 1:51 pm
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
- Jan 3rd, 2024 12:00 pm
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System
- Dec 20th, 2023 12:00 pm
InspireMD's Gary Roubin Acquires 13% More Stock
- Dec 6th, 2023 10:03 am
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
- Nov 27th, 2023 12:00 pm
InspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call Transcript
- Nov 7th, 2023 2:12 pm
InspireMD Inc (NSPR) Reports Q3 2023 Financial Results: CGuard EPS Revenue Increases by 9% ...
- Nov 6th, 2023 1:11 pm
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 6th, 2023 12:00 pm
InspireMD to Participate in Upcoming November Investor Conferences
- Nov 2nd, 2023 12:00 pm
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23
- Nov 1st, 2023 6:19 pm
InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th
- Oct 30th, 2023 1:21 pm
InspireMD's (NASDAQ:NSPR) investors will be pleased with their impressive 179% return over the last year
- Oct 23rd, 2023 10:51 am
InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients
- Oct 12th, 2023 11:00 am
InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives
- Oct 3rd, 2023 11:00 am
Scroll